Why FDA Regulations on Peptide Therapy Matter for Patient Safety and Access
FDA scrutiny of peptide therapy compounds raises questions about balancing patient access with safety standards.
-
-
Peptide Therapy Surges in Popularity as Medical Experts Urge Caution on Unregulated Use
Medical experts warn against unregulated peptide therapy despite surging popularity driven by social media wellness trends.
-
Eli Lilly Launches Zepbound KwikPen at $399 Self-Pay Price, Undercutting Compounders
Eli Lilly introduces Zepbound KwikPen at $399 monthly, directly competing with compounded tirzepatide alternatives.
-
Novo Nordisk Reports Positive Phase 3 Results for CagriSema in NASH
Novo Nordisk’s CagriSema combination therapy shows promise for treating NASH in Phase 3 trial published in NEJM.
-
FDA Issues Warning Letters to 14 Compounding Pharmacies Over GLP-1 Peptide Purity
FDA warns 14 compounding pharmacies for inadequate purity testing of semaglutide and tirzepatide peptides amid growing demand.
-
Stem Cell-Derived Exosomes Show Promise for Knee Osteoarthritis in Randomized Trial
Stem cell exosome injections improved pain and function in knee osteoarthritis patients in a randomized trial.
-
EU Moves Toward Standardized Peptide Therapy Framework
EMA proposes unified regulatory framework for peptide therapeutics to standardize approval and safety monitoring across EU member states.
-
Orforglipron Oral GLP-1 Meets Primary Endpoint in ACHIEVE-4 Cardiovascular Trial
Eli Lilly’s oral GLP-1 orforglipron met its primary cardiovascular endpoint in ACHIEVE-4 trial per JAMA Cardiology.
-
UK Calls for Emergency Ban on Non-Surgical Breast Fillers After Serious Complications
UK moves to ban breast filler injections after serious complications lead to infections and tissue damage requiring surgery.
-
Allergan’s Next-Gen Neurotoxin Shows Faster Onset in Phase 2 Results
Allergan’s experimental neurotoxin shows visible results in 24 hours, potentially eliminating the typical multi-day waiting period.
